Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants with acute myeloid leukemia and myelodysplastic syndromes. The main question it aims to answer is whether or not providing a new, gentler way of administering chemotherapy will help control leftover cancer with minimal side effects. This treatment involves decitabine and venetoclax. Participants will receive standard post-transplant care. Participants will be administered decitabine once per week with normal transplant follow up visits, and then will take a venetoclax pill about 6 to 8 hours later. Participants will meet their study team at the beginning, midway, and at the end of the trial to receive bone marrow testing. Participants will receive treatment until either one year of therapy, relapse, or recurrent dose limiting toxicity (DLT) despite dose reduction.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza ostra białaczka szpikowa, zespół mielodysplastyczny lub kombinacja obu, wymagająca przeszczepu szpiku kostnego
- •Wiek co najmniej 18 lat
- •Zaplanowany lub już przeprowadzony przeszczep szpiku kostnego
- •Prawidłowa funkcja wątroby i nerek (parametry w normie)
- •Dobry ogólny stan zdrowia (zdolny do samodzielnego funkcjonowania)
- •Pomyślne przyjęcie przeszczepu potwierdzone wynikami krwi
- •Brak aktywnego zapalenia w organizmie
- •Brak lub lekkie objawy powikłań związanych z przeszczepem
✗ Disqualifies
- •Inna planowana terapia utrzymująca po przeszczepie
- •Ciąża lub karmienie piersią
- •Dodatni test ciąży w ciągu 72 godzin przed rozpoczęciem leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Cleveland, United States
University Hospitals Seidman Cancer, Case Comprehensive Cancer Center
Cleveland, United States
Trial contact
Benjamin Tomlinson, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.